𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: A phase II study with a 5-year follow-up

✍ Scribed by Alfredo Berruti; Enrica Fara; Marcello Tucci; Roberto Tarabuzzi; Alessandra Mosca; Carlo Terrone; Gabriella Gorzegno; Giuseppe Fasolis; Marco Tampellini; Francesco Porpiglia; Marinella De Stefanis; Dario Fontana; Oscar Bertetto; Luigi Dogliotti

Book ID
116955637
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
163 KB
Volume
23
Category
Article
ISSN
1078-1439

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Oral estramustine and cyclophosphamide i
Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma : A phase II study
✍ Sergio Bracarda; Maurizio Tonato; Paolo Rosi; Verena De Angelis; Ettore Mearini; πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 2 views

## BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxi

Weekly paclitaxel, estramustine phosphat
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma : Results of a Minnie Pearl Cancer Research Network Phase II Trial
✍ Anthony A. Meluch; F. Anthony Greco; Lisa H. Morrissey; Eric L. Raefsky; Ronald πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 87 KB πŸ‘ 2 views

## Abstract ## BACKGROUND The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone‐refractory prostate carcinoma. ## METHODS Patients with hormone‐refractory p